NSE Healthcare Drug Manufacturers - Specialty & Generic IPCALAB.NS

Ipca Laboratories Limited

$ 1 590.20 3.02 %

Ipca Laboratories Limited is a pharmaceutical company that manufactures and distributes a comprehensive range of finished drug products (formulations) and essential raw materials, known as Active Pharmaceutical Ingredients (APIs). Its API portfolio supports treatments for conditions such as hypertension, malaria, parasitic infections, and also includes diuretics and disease-modifying anti-rheumatic drugs (DMARDs). The company provides an extensive selection of generic and branded formulations across numerous therapeutic segments. These encompass cardiovascular health, diabetes management, neurological disorders, gastroenterology, and dermatology. Furthermore, Ipca's product lines address oncology, rheumatology, respiratory conditions, ophthalmology, urology, mental health, infectious diseases, pain management, allergies, nutritional support, and various other specialized medical requirements. Primarily operating in India, Ipca Laboratories also boasts a significant international footprint, exporting its products to approximately 100 countries worldwide. The company, which has its headquarters in Mumbai, India, was established in 1949.

CEO: Pranay Premchand Godha - https://www.ipca.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 1 114.16

Loading data...

IPCALAB.NS vs S&P500

Loading data...

No data available.

Quick ratio

1.58

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

35.31

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

45.04

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

14.81 %

reflects reasonable profitability, showing good use of equity.

ROIC

16.49 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.21

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.10

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

12.56

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

4.62 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
10.09 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.24 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.07 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.